ANDRIANI , Lilia

Carbapenemase-producing Enterobacterales (CPE) represent a major cause of difficult-to-treat infections worldwide. The novel β-lactam/β-lactamase inhibitor combinations (BLICs), including ceftazidime/avibactam (CZA), meropenem/vaborbactam (MVB), and imipenem/relebactam (IMR), represented a breakthrough to treat some CPE infections. However,...